BOSTON, Mass. – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, today announces positive data from its Phase Ib/IIa study in Parkinson’s disease patients, evaluating the effects of its oral, brain-penetrant NLRP3 inflammasome inhibitor NT-0796, on inflammatory and disease-specific biomarkers in the blood...
treatment News
WASHINGTON, DC — The future of rare disease advancements will take center stage at the National Organization for Rare Disorders (NORD®) Rare Disease and Orphan Products Breakthrough Summit®, Oct. 19-21 in Washington. NORD is proud to announce the top researchers selected for the Lightning Rounds Poster Presentations session. Chosen from a competitive...
EVANSTON, Ill. — Researchers led by Northwestern University and Washington University School of Medicine in St. Louis have developed a new, first-of-its-kind sticker that enables clinicians to monitor the health of patients’ organs and deep tissues with a simple ultrasound device. When attached to an organ, the soft, tiny sticker...
Chicago, Ill. – Millions of people take metformin, a Type 2 diabetes medication that lowers blood sugar. The “wonder drug” has also been shown to slow cancer growth, improve COVID outcomes and reduce inflammation. But until now, scientists have been unable to determine how, exactly, the drug works. ...
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognize and eliminate cancer cells before tumors develop Final...
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation off-the-shelf and personalized neoantigen cancer immunotherapies, today announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. Following positive safety and immunogenicity data reported at...
Mont Saint-Guibert and Brussels, Belgium – Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, and the Cliniques universitaires Saint-Luc today announce the successful treatment of four pediatric patients with Congenital Pseudarthrosis of the Tibia (CPT) using NVD003, an autologous therapy developed by Novadip for the reconstruction of...
Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s...
Mont Saint-Guibert, Belgium – Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces the recruitment of the first pediatric patients for the pivotal phase 3 trial of its tissue regeneration product NVD003 in congenital pseudoarthrosis of the tibia (CPT). Phoenix Children’s Hospital, (Phoenix, AZ, USA), and...
Basel, Switzerland – Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren’s disease. Both trials met the primary endpoint of demonstrating statistically significant improvements in disease activity1. These results support the potential for ianalumab, a drug with a dual mechanism...